سعر نيريسيد 0.1% كريم 10جم 2022

Diflucortolone valerate 0.1% topical cream (10 g tube) by CID, Egypt; potent topical corticosteroid.

• All skin diseases that respond to topical corticosteroid therapy, in the absence of infection.CID EXPORT product gallery (cid.do.am)
• Topical treatment of corticosteroid-responsive dermatoses that are unresponsive to less potent corticosteroids and in the absence of infection.MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• With large areas (about 10% or more) and/or long use (more than 4 weeks), particularly with the fatty ointment or occlusion: skin atrophy, telangiectasia, striae, acneiform changes and systemic corticosteroid effects; topical corticosteroids may be hazardous in psoriasis.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Common local reactions: burning, pruritus, erythema and irritation. With large areas (10% or more) or long use (more than 4 weeks), especially with occlusion: skin atrophy, telangiectasia, striae, acneiform changes, perioral dermatitis, hypertrichosis and systemic corticosteroid effects; rarely allergic skin reactions.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Tuberculous or syphilitic processes in the treated area; viral diseases (e.g. vaccinia, chickenpox); rosacea and perioral dermatitis; acne vulgaris; undiagnosed perianal and genital pruritus; napkin rash; primary bacterial or fungal skin infections or broken skin; secondary infections without anti-infective therapy; ophthalmic conditions. Large amounts or prolonged use should be avoided in the first trimester of pregnancy.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Rosacea and perioral dermatitis; acne vulgaris; undiagnosed perianal and genital pruritus; napkin eruptions; viral infections; primary bacterial or fungal skin infections; secondary infections without appropriate anti-infective therapy; post-vaccination skin reactions in the treated area; ophthalmic conditions; hypersensitivity to the active substance or excipients.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Use occlusive dressings with caution (possible suppression of natural steroid production); bacterial or fungal skin infections need additional specific therapy; avoid contact with the eyes when applied to the face; switch to a fattier form if the skin dries out under prolonged cream use.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Adrenal suppression can occur even without occlusion; systemic absorption increases with occlusion, large areas or prolonged use.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Use in psoriasis may be hazardous (rebound relapse, generalised pustular psoriasis, local and systemic toxicity); careful supervision is needed.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Inadequate evidence of safety in human pregnancy; topical corticosteroids in pregnant animals can cause foetal abnormalities (e.g. cleft palate, intra-uterine growth retardation); application to large areas or for prolonged periods must be avoided.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Side effects in neonates cannot be excluded after extensive or prolonged maternal use during pregnancy or lactation; nursing mothers should not apply it to the breasts.International label, same formulation · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Diflucortolone valerate: Suppresses cutaneous inflammation and alleviates pruritus/burning in inflammatory dermatoses.